Novel approaches to treatment of double-refractory multiple myeloma.
about
Double Relapsed and/or Refractory Multiple Myeloma: Clinical Outcomes and Real World Healthcare CostsAnalysis of Real-World Data on Overall Survival in Multiple Myeloma Patients With ≥3 Prior Lines of Therapy Including a Proteasome Inhibitor (PI) and an Immunomodulatory Drug (IMiD), or Double Refractory to a PI and an IMiD.New Insights in the Cytogenetic Practice: Karyotypic Chaos, Non-Clonal Chromosomal Alterations and Chromosomal Instability in Human Cancer and Therapy ResponseThe glutathione synthesis inhibitor buthionine sulfoximine synergistically enhanced melphalan activity against preclinical models of multiple myeloma.Leveraging the new with the old: providing a framework for the integration of historic microarray studies with next generation sequencing.Identification of markers that functionally define a quiescent multiple myeloma cell sub-population surviving bortezomib treatmentKyprolis (Carfilzomib) Received New Indications as Combination Therapy for Use in Relapsed and/or Refractory Multiple Myeloma.Darzalex (Daratumumab): First Anti-CD38 Monoclonal Antibody Approved for Patients with Relapsed Multiple MyelomaPomalyst (Pomalidomide) Received a New Indication for Patients with Relapsed and/or Refractory Multiple Myeloma.Aseptic necrosis at multiple localisations in a lupus patient with lymphoma.Deptor transcriptionally regulates endoplasmic reticulum homeostasis in multiple myeloma cells.Mechanisms and clinical applications of chromosomal instability in lymphoid malignancy.
P2860
Q28547963-CF15B126-633B-4E06-831C-DFAE45548BAAQ31119290-4010202A-0B3A-488A-89E2-866B5E164FF4Q33836777-93E14D47-EF52-4D7A-A5D4-663C8B76C109Q34448863-5893794F-9D33-45A4-B378-8BB097143CFFQ34606998-41322414-5F12-4D30-9C24-36EF542CBEBAQ35663049-52D712F7-A8A7-4631-83ED-C2E626F3F4B7Q37237666-D96A6CF9-0A6E-4DBF-8973-498D3A4243E9Q37237708-F2146D0B-A44A-4E8D-83A5-E491154AB647Q37237715-1AD5B894-4075-45E8-AD60-07C11DAC6C76Q37638876-83892F91-27D9-4D49-976E-F5BA8A234FEAQ37688571-4E52D7EF-DD64-4C7E-827D-27376BF319B1Q38504989-14FC2CB6-1F86-489A-803B-42AAEA46EE7C
P2860
Novel approaches to treatment of double-refractory multiple myeloma.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Novel approaches to treatment of double-refractory multiple myeloma.
@ast
Novel approaches to treatment of double-refractory multiple myeloma.
@en
Novel approaches to treatment of double-refractory multiple myeloma.
@nl
type
label
Novel approaches to treatment of double-refractory multiple myeloma.
@ast
Novel approaches to treatment of double-refractory multiple myeloma.
@en
Novel approaches to treatment of double-refractory multiple myeloma.
@nl
prefLabel
Novel approaches to treatment of double-refractory multiple myeloma.
@ast
Novel approaches to treatment of double-refractory multiple myeloma.
@en
Novel approaches to treatment of double-refractory multiple myeloma.
@nl
P2860
P1476
Novel approaches to treatment of double-refractory multiple myeloma.
@en
P2093
Hans C Lee
Jatin J Shah
P2860
P356
10.1200/EDBOOK_AM.2013.33.E302
P577
2013-01-01T00:00:00Z